Search results
Showing 1 to 7 of 7 results for levothyroxine
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.
This indicator covers the percentage of patients with hypothyroidism, on the register, with thyroid function tests recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM100
NG145/1 Question What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared...
NG145/7 Question What is the clinical and cost effectiveness of levothyroxine for people under 65 with symptomatic subclinical...
Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (IPG562)
Evidence-based recommendations on ultrasound-guided percutaneous radiofrequency ablation for treating benign thyroid nodules in adults. This involves using heat energy to destroy tissue in the nodules.
NG145/1 | What is the clinical and cost effectiveness of levothyroxine (T4) and liothyronine (T3) combination therapy compared with T4...